Zydus Lifesciences rises on getting USFDA's final nod for Erythromycin Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 472.70, up by 3.75 points or 0.80% from its previous closing of Rs. 468.95 on the BSE.
The scrip opened at Rs. 468.00 and has touched a high and low of Rs. 473.70 and Rs. 465.80 respectively. So far 22582 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 479.40 and Rs. 465.80 respectively. The current market cap of the company is Rs. 47467.31 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 16.21% and 8.81% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Erythromycin Tablets USP, 250 mg and 500 mg (USRLD: Erythromycin Tablets). Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, legionnaire's disease, pertussis and syphilis.
The drugs will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India). Erythromycin Tablets USP, 250 mg and 500 mg had annual sales of $25.1 million in the United States (IQVIA MAT Dec. 2022). The group now has 350 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
